Effect of an intensive smoking cessation intervention on smoking cessation and disease activity in patients with rheumatoid arthritis: a randomised controlled trial

Rheumatoid Arthritis

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial

Ann Rheum Dis

van Mulligen E, Bour SS, Goossens LMA, de Jong PHP, Rutten-van Mölken M, van der Helm-van Mil A

doi: 10.1136/ard-2024-226286

Rheumatoid Arthritis

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

Arthritis Res Ther

Ramien R, Rudi T, Alten R, Krause A, Schneider M, Schaefer M, Strangfeld A, Meissner Y

doi: 10.1186/s13075-024-03449-9

Rheumatoid Arthritis

A mobile app to support self-management and remotely monitor disease impact in rheumatoid arthritis: the randomised controlled AEGORA trial

Rheumatology (Oxford)

Doumen M, De Meyst E, Bertrand D, Pazmino S, Piessens M, Joly J, Devinck M, Westhovens R, Verschueren P

doi: 10.1093/rheumatology/keae638

Further Publications Immunology

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Lancet

Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE, VIVID Study Group

doi: 10.1016/S0140-6736(24)01762-8

Psoriatic Arthritis

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Ther Adv Musculoskelet Dis

Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh JA

doi: 10.1177/1759720X241288071

Rheumatoid Arthritis

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study

Rheumatol Ther

Taylor PC, Fakhouri W, Ogwu S, Haladyj E, de la Torre I, Fautrel B, Alten R, Nash P, Feist E

doi: 10.1007/s40744-024-00732-8

Rheumatoid Arthritis

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Semin Arthritis Rheum

Dieudé P, Sparks JA, Fischer A, Chen L, Lozenski K, Dahan S, Chaballa M, Little W

doi: 10.1016/j.semarthrit.2025.152795

Rheumatoid Arthritis

Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial

Ann Rheum Dis

Wientjes MHM, Atiqi S, Wolbink GJ, Nurmohamed MT, Boers M, Hooijberg F, Rispens T, de Vries A, van Vollenhoven RF, Ramiro S, van Herwaarden N, van den Bemt BJF, den Broeder AA

doi: 10.1016/j.ard.2025.03.015

Psoriatic Arthritis

Patient profiles in randomised controlled trials versus a real-world study, in psoriatic arthritis: scoping review and meta-analysis

J Rheumatol

Alle G, Lopez-Medina C, Siebert S, Lavie F, Noel W, Smolen JS, Gossec L

doi: 10.3899/jrheum.2024-0653

Related content

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

A mobile app to support self-management and remotely monitor disease impact in rheumatoid arthritis: the randomised controlled AEGORA trial

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial

Patient profiles in randomised controlled trials versus a real-world study, in psoriatic arthritis: scoping review and meta-analysis